Table 1 Clinicopathologic characteristics
Endometrial Carcinoma(N%) | Uterine Sarcoma(N%) | |
|---|---|---|
Total | 47 | 37 |
Age at recurrence,years (mean, range) | 55 ± 9.441 (29–76) | 50.92 ± 10.652 (34–74) |
ECOG performance status before SCS | ||
0 | 41 (87.2) | 32 (86.5) |
1 | 5 (10.6) | 4 (10.8) |
2 | 1 (2.1) | 1 (2.7) |
FIGO stage at initial diagnosis | ||
I | 33 (70.2) | 28 (75.7) |
II | 2 (4.3) | 4 (10.8) |
III | 9 (19.1) | 4 (10.8) |
IV | 3 (6.4) | 1 (2.7) |
Histology | ||
Endometrioid | 38 (80.9) | NA |
G1 | 9 (23.7) | NA |
G1-G2 | 5 (13.2) | NA |
G2 | 5 (13.2) | NA |
G2-G3 | 7 (18.4) | NA |
G3 | 12 (31.6) | NA |
Serous | 3 (6.4) | NA |
Clear cell | 1 (2.1) | NA |
Carcinosarcoma | 5 (10.6) | NA |
Uterine leiomyosarcoma | NA | 19 (51.4) |
Low-grade endometrial stromal sarcoma | NA | 11 (29.7) |
High-grade endometrial stromal sarcoma | NA | 3 (8.1) |
Other | NA | 4 (10.8) |
Primary treatment | ||
Surgery | 100 (100) | 36 (97.3) |
Chemotherapy | 0 (0) | 1 (2.7) |
Primary treatment in our hospital | ||
Yes | 9 (19.1) | 4 (10.8) |
No | 38 (80.9) | 33 (89.2) |
Adjuvant treatment after first surgery | ||
None | 29 (61.7) | 28 (75.7) |
Chemotherapy only | 7 (14.9) | 7 (18.9) |
Radiotherapy only | 6 (12.8) | 0 (0) |
Combined chemoradiotherapy | 2 (4.3) | 0 (0) |
Hormonal therapy | 3 (6.4) | 1 (2.7) |
Other | 0 (0) | 1 (2.7) |
DFI, months (median, range) | 14 (1–96) | 11 (2-109) |